Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Patient Demographics and Referral Patterns for [F-18]Fluciclovine-PET Imaging at a Tertiary Academic Medical CenterJournal of the American College of Radiology.  16:315-320. 2019
2019 Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective TrialAdvances in Radiation Oncology.  4:90-95. 2019
2019 Targeting DNA repair in precision medicineAdvances in Protein Chemistry and Structural Biology.  115:135-155. 2019
2018 The antitumor effects of entinostat in ovarian cancer require adaptive immunityCancer.  124:4657-4666. 2018
2018 First-line treatment of widely metastatic BRAF-mutated salivary duct carcinoma with combined BRAF and MEK inhibitionJournal of the National Comprehensive Cancer Network.  16:1166-1170. 2018
2018 Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic TargetsEuropean urology focus.  4:733-736. 2018
2018 Reply to "phase II prospective randomized trial of weight loss prior to radical prostatectomyProstate Cancer and Prostatic Diseases.  21:293-294. 2018
2018 Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinomaCell Growth and Differentiation.  16:813-824. 2018
2018 Trastuzumab-resistant HER2 þ breast cancer cells retain sensitivity to poly (adp-ribose) polymerase (parp) inhibitionMolecular Cancer Therapeutics.  17:921-930. 2018
2018 Stereotactic Radiosurgery for Prostate Cancer Following Magnetic Resonance Imaging Directed Biopsy: A Multidisciplinary Approach with Case Examples.Cureus.  10:e2524. 2018
2018 Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer [Oncotarget., 7, (2016) (86803-86815)] 10.18632/oncotarget.13466Oncotarget.  9:19459-19459. 2018
2018 JQ1 induces DNA damage and apoptosis, and inhibits tumor growth in a patient-derived xenograft model of cholangiocarcinomaMolecular Cancer Therapeutics.  17:107-118. 2018
2018 ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damageJournal of Biological Chemistry.  293:984-994. 2018
2017 Subcutaneous adipose tissue characteristics and the risk of biochemical recurrence in men with high-risk prostate cancerUrologic Oncology: Seminars and Original Investigations.  35:663.e15-663.e21. 2017
2017 The impact of DNA repair pathways in cancer biology and therapyCancers.  9. 2017
2017 DNA repair deregulation in discrete prostate cancer lesions identified on multi-parametric MRI and targeted by MRI/ultrasound fusion-guided biopsy.Oncotarget.  8:68038-68046. 2017
2017 Implementation and utilization of the molecular tumor board to guide precision medicine.Oncotarget.  8:57845-57854. 2017
2017 A step towards predicting checkpoint inhibitor response in kidney cancerLancet Oncology.  18:982-983. 2017
2017 DNA repair deregulation in discrete prostate cancer lesions identified on multi-parametric MRI and targeted by MRI/ultrasound fusion-guided biopsy.Oncotarget2017
2017 Combining Chk1/2 inhibition with cetuximab and radiation enhances in vitro and in vivo cytotoxicity in head and neck squamous cell carcinomaMolecular Cancer Therapeutics.  16:591-600. 2017
2017 CT measures of bone mineral density and muscle mass can Be used to predict noncancer death in men with prostate cancerRadiology.  282:475-483. 2017
2017 Let-7 status is crucial for PARP1 expression in HER2-overexpressing breast tumorsCell Growth and Differentiation.  15:340-347. 2017
2017 MARCKS phosphorylation is modulated by a peptide mimetic of MARCKS effector domain leading to increased radiation sensitivity in lung cancer cell linesOncology Letters.  13:1216-1222. 2017
2017 Poly(ADP-ribose) polymerase activity and inhibition in cancerSeminars in Cell and Developmental Biology.  63:144-153. 2017
2017 DNA-PkCS expression in oropharyngeal squamous cell carcinoma: Correlations with human papillomavirus status and recurrence after transoral robotic surgeryHead & neck surgery.  39:206-214. 2017
2017 Implementation and utilization of the molecular tumor board to guide precision medicineOncotarget.  8:57845-57854. 2017
2017 Kinase analysis of penile squamous cell carcinoma on multiple platforms to identify potential therapeutic targetsOncotarget.  8:21710-21718. 2017
2017 Presurgical weight loss affects tumour traits and circulating biomarkers in men with prostate cancerBritish Journal of Cancer.  117:1303-1313. 2017
2016 Potential biomarkers for radiosensitivity in head and neck cancersAnnals of translational medicine.  4. 2016
2016 Notch signaling activation is associated with patient mortality and increased FGF1-mediated invasion in squamous cell carcinoma of the oral cavityCell Growth and Differentiation.  14:883-891. 2016
2016 Kinase gene expression profiling of metastatic clear cell renal cell carcinoma tissue identifies potential new therapeutic targetsPLoS ONE.  11. 2016
2016 Current and emerging clinical applications of multispectral optoacoustic tomography (MSOT) in oncologyClinical Cancer Research.  22:3432-3439. 2016
2016 The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft modelsOncogene.  35:833-845. 2016
2016 Niclosamide and its analogs are potent inhibitors of Wnt/ß- catenin, mTOR and STAT3 signaling in ovarian cancerOncotarget.  7:86803-86815. 2016
2016 Pelvic radiotherapy versus radical prostatectomy with limited lymph node sampling for high-grade prostate adenocarcinomaProstate Cancer.  2016. 2016
2016 Prostate Radiotherapy in the Era of Advanced Imaging and Precision MedicineProstate Cancer.  2016. 2016
2015 Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutritionSeminars in Cancer Biology.  35:S5-S24. 2015
2015 Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 InhibitionBMC Cancer.  15. 2015
2015 Effect of African-American Race on Tumor Recurrence after Radical Cystectomy for Urothelial Carcinoma of the BladderClinical Genitourinary Cancer.  13:469-475. 2015
2015 PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancersBreast Cancer Research and Treatment.  150:569-579. 2015
2015 Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥3 cmHPB.  17:140-149. 2015
2015 DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinomaOncotarget.  6:26995-27007. 2015
2015 Designing a broad-spectrum integrative approach for cancer prevention and treatmentSeminars in Cancer Biology.  35:S276-S304. 2015
2015 Targeting the effector domain of the myristoylated alanine rich C-kinase substrate enhances lung cancer radiation sensitivityInternational Journal of Oncology.  46:1079-1088. 2015
2015 The protective effect of p16 INK4a in oral cavity carcinomas: p16 Ink4A dampens tumor invasion-integrated analysis of expression and kinomics pathwaysModern Pathology.  28:631-653. 2015
2014 Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapyRadiation Oncology.  9. 2014
2014 Concentration calibration of urine biomarkers for diagnosis improvement of ovarian cancerInternational Journal of Bio-Science and Bio-Technology.  6:65-72. 2014
2014 Epigenetic inactivation of DNA repair in breast cancerCancer Letters.  342:213-222. 2014
2014 Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damageAnti-Cancer Drugs.  25:878-886. 2014
2014 An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancerGynecologic Oncology.  134:331-337. 2014
2014 Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolinesRadiotherapy and Oncology.  111:468-474. 2014
2014 PSA response to neoadjuvant androgen deprivation is an independent prognostic marker and may identify patients who benefit from treatment escalationUrologic Oncology: Seminars and Original Investigations.  32:687-693. 2014
2014 Reduced radiation tolerance of penile structures associated with dose-escalated hypofractionated prostate radiotherapyUrology.  84:1383-1388. 2014
2014 The Smad7-Skp2 complex orchestrates Myc stability, impacting on the cytostatic effect of TGF-βJournal of Cell Science.  127:411-421. 2014
2013 Beyond DNA repair: Additional functions of PARP-1 in cancerFrontiers in Oncology.  3 NOV. 2013
2013 PARP-1: Friend or foe of DNA damage and repair in tumorigenesis?Cancers.  5:943-958. 2013
2013 Segmentation editing improves efficiency while reducing inter-expert variation and maintaining accuracy for normal brain tissues in the presence of space-occupying lesionsPhysics in Medicine and Biology.  58:4071-4097. 2013
2013 BRCA1-Ku80 protein interaction enhances end-joining fidelity of chromosomal double-strand breaks in the G1 phase of the cell cycleJournal of Biological Chemistry.  288:8966-8976. 2013
2013 Discussion of PARP inhibitors in cancer therapyPharmaceutical Patent Analyst.  2:755-766. 2013
2013 Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancerClinical Cancer Research.  19:170-182. 2013
2012 Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-Ribose) polymerase inhibitionCancer Research.  72:5547-5555. 2012
2012 Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer CellsPLoS ONE.  7. 2012
2012 HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repairCancer Research.  72:4796-4806. 2012
2012 The intersection between DNA damage response and cell death pathwaysEksperimental'naia onkologiia.  34:243-254. 2012
2012 Biomarkers to assess the targeting of DNA repair pathways to augment tumor response to therapyCurrent Molecular Medicine.  12:788-803. 2012
2012 Kinomic profiling approach identifies Trk as a novel radiation modulatorRadiotherapy and Oncology.  103:380-387. 2012
2012 MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for gliomaClinical Cancer Research.  18:3030-3041. 2012
2012 Assaying DNA damage in hippocampal neurons using the comet assay.Journal of Visualized Experiments2012
2012 Hypofractionated Prostate Radiotherapy with or without Conventionally Fractionated Nodal Irradiation: Clinical Toxicity Observations and Retrospective Daily Dosimetry.Prostate Cancer.  2012:546794. 2012
2011 Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiationRadiotherapy and Oncology.  101:183-189. 2011
2011 Cetuximab augments cytotoxicity with poly (ADP-Ribose) polymerase inhibition in head and neck cancerPLoS ONE.  6. 2011
2011 p53-dependent BRCA1 nuclear export controls cellular susceptibility to DNA damageCancer Research.  71:5546-5557. 2011
2011 Comparison of manual and automatic segmentation methods for brain structures in the presence of space-occupying lesions: A multi-expert studyPhysics in Medicine and Biology.  56:4557-4577. 2011
2011 Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinomaRadiotherapy and Oncology.  99:339-343. 2011
2011 The poly(ADP-ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapyRadiotherapy and Oncology.  99:331-338. 2011
2011 Glycogen synthase kinase 3β inhibition enhances repair of DNA double-strand breaks in irradiated hippocampal neuronsNeuro-Oncology.  13:459-470. 2011
2011 Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors.Frontiers in Molecular Neuroscience.  4:47. 2011
2010 BRCA1 16 years later: DNA damage-induced BRCA1 shuttlingEuropean Journal of Biochemistry.  277:3079-3085. 2010
2010 DNA damage-induced cytotoxicity is dissociated from BRCA1's DNA repair function but is dependent on its cytosolic accumulationCancer Research.  70:6258-6267. 2010
2010 Reduction of Dose Delivered to Organs at Risk in Prostate Cancer Patients via Image-Guided Radiation TherapyInternational Journal of Radiation Oncology - Biology - Physics.  76:924-934. 2010
2009 Evolution of clinical trials in head and neck cancerCritical Reviews in Oncology/Hematology.  71:29-42. 2009
2009 Lithium-mediated protection of hippocampal cells involves enhancement of DNA-PK-dependent repair in miceJournal of Clinical Investigation.  119:1124-1135. 2009
2009 Refractory lympho-epithelial carcinoma of the nasopharynx: a case report illustrating a protracted clinical course.Head and Neck Oncology.  1:18. 2009
2008 Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cellsCancer Research.  68:9141-9146. 2008
2007 Autophagy signaling in cancer and its potential as novel target to improve anticancer therapyDrug Resistance Updates.  10:135-143. 2007
2007 The role of mTOR inhibition in augmenting radiation induced autophagyTechnology in Cancer Research and Treatment.  6:443-447. 2007
2004 Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21CIP1 levels in androgen-independent human prostate cancer cellsOncogene.  23:5513-5522. 2004
2003 Vitamin D Inhibits G1 to S Progression in LNCaP Prostate Cancer Cells through p27Kip1 Stabilization and Cdk2 Mislocalization to the CytoplasmJournal of Biological Chemistry.  278:46862-46868. 2003
2002 Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancerMolecular and Cellular Endocrinology.  186:69-79. 2002
1999 Abnormal regulation of DNA methyltransferase expression during colorectal carcinogenesisCancer Research.  59:3855-3860. 1999

Research Overview

  • Many cancer therapies attack cellular DNA to cause DNA damage. The DNA double strand break (DSB) is the most critical form of DNA damage that induces both normal and cancer cell death if left unrepaired. My research interests involve the targeting of DNA repair pathways to enhance the therapeutic ratio. We aim to discover novel strategies to augment DNA repair pathways to specifically protect normal cells from DNA damage while reducing DNA repair capacity to convert cancer cells to become more susceptible to DNA damaging agents. Ultimately, we hope to translate our work into the clinic to deferentially treat cancer while sparing normal cells to maintain quality of life.

    Keywords - nanostring, profiling, DNA damage, DNA repair, EGFR, cancer, PARP, apoptosis, brain, protection, GSK3
  • Principal Investigator On

  • Phase IB Trial of Radium-223 and Niraparib in Patients with Castrate Resistant Prostate Cancer  awarded by THOMAS JEFFERSON UNIVERSITY - NEW 2018 - 2023
  • Private Grant  awarded by ASTRAZENECA AB 2018 - 2023
  • Private Grant  awarded by CLOVIS ONCOLOGY 2017 - 2022
  • Private Grant  awarded by CLOVIS ONCOLOGY 2017 - 2022
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology 2017 - 2019
  • Private Grant  awarded by PROSTATE CANCER CLINICAL TRIALS CONSORTIUM, LLC 2017 - 2019
  • Exploiting TNBC Vulnerabilities Via Rationally Combined Therapies  awarded by American Association for Cancer Research 2015 - 2019
  • Private Grant  awarded by ELI LILLY AND COMPANY 2016 - 2019
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2017 - 2018
  • Biomarkers for Detection of Renal Cell Carcinoma  awarded by American Cancer Society, Inc. 2017 - 2018
  • Private Grant  awarded by ELI LILLY AND COMPANY 2016 - 2018
  • Private Grant  awarded by ELI LILLY AND COMPANY 2016 - 2018
  • Private Grant  awarded by ELI LILLY AND COMPANY 2013 - 2017
  • DNA Repair Independent Mechanisms of HER2+ Tumor Sensitivity to PARP Inhibition  awarded by Komen (Susan G.) Breast Cancer Foundation 2013 - 2017
  • Mechanisms by Which GSK3B Inhibition Enhances Nonhomologous End-Joining Repair  awarded by GABRIELLE'S ANGELS 2011 - 2015
  • Private Grant  awarded by ABBOTT LABORATORIES 2012 - 2014
  • HER2 Overexpression Confers Susceptibility to PARP Inhibition  awarded by American Association for Cancer Research 2012 - 2014
  • Elevated NF-kB Signaling in Breast Cancers of African American Women  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE 2013
  • Targeting Homology-Directed Recombinational Repair (HDR) of Chromosomal Breaks to Sensitize Prostate Cancer Cells to Poly (ADP-Ribose) Polymerase (PARP) Inhibition  awarded by DOD - Department of Defense 2010 - 2013
  • Can Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling Induce Synthetic Lethality with Poly (ADP-Ribose) Polymerase Inhibition (PARPi) by Generating a DNA Repair Defect?  awarded by Kimmel (Sidney) Foundation for Cancer Research 2011 - 2013
  • Investigator On

  • Mechanism of Ultraviolet Radiation Induced Immune Tolerance  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2018 - 2023
  • Quantitative Imaging To Personalize Therapy in Her2 Breast Cancer  awarded by American Cancer Society, Inc. 2019 - 2022
  • RTOG Foundation Master Service Agreement for Participation in Foundation Research: RTOG 3501 Tryhard: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb) for Non-HPV Locally Advanced Head and Neck Cancer with Concurrent Chemoradiation  awarded by American College of Radiology 2012 - 2022
  • Deciphering How Esco2 Loss Acts as a Penetrance Modifier  awarded by National Cancer Institute/NIH/DHHS 2017 - 2022
  • Developing Novel Combination Therapies for Pancreatic Cancer  awarded by National Cancer Institute/NIH/DHHS 2016 - 2021
  • A New Paradigm: Using PARP Inhibitors to Treat HER2+ Breast Cancer  awarded by Komen (Susan G.) Breast Cancer Foundation 2018 - 2021
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2017 - 2021
  • Private Grant  awarded by IMAGINAB 2019 - 2021
  • Developing Therapy for the Treatment of Cholangiocarcinoma  awarded by National Cancer Institute/NIH/DHHS 2016 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2014 - 2019
  • Using the Genomic Profile of High Intermediate Risk Endometrial Cancer Patients to Differentiate Patients at High Risk of Recurrence from the Majority with Low Risk of Recurrence  awarded by FOUNDATION FOR GYNECOLOGIC ONCOLOGY 2016 - 2017
  • Private Grant  awarded by Novartis Pharma AG 2014 - 2017
  • Private Grant  awarded by SUCAMPO PHARMACEUTICALS 2016
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2013 - 2015
  • Private Grant  awarded by ABBVIE INC 2014 - 2015
  • Education And Training

  • Doctor of Medicine, University of Miami 2005
  • Doctor of Philosophy in Molecular Pharmacology, University of Miami 2005
  • Mount Sinai Hospital, Internship 2006
  • Vanderbilt University Medical Center, Residency 2010
  • Full Name

  • Eddy Yang